Tune Therapeutics
Matt Gemberling has worked in the field of research for over 14 years. From 2020 to present, Gemberling has held the roles of Associate Director of Research, Founding Scientist, and Senior Scientist at Tune Therapeutics. From 2008-2020, Gemberling was a Postdoctoral Associate and Graduate Student at Duke University. From 2006-2008, Gemberling was a Research Technician at Brown University's Fairbrother Lab.
Matt Gemberling completed a Bachelor of Science (BS) in Biology, General from Davidson College between 2002 and 2006. Matt then went on to earn their Doctor of Philosophy (Ph.D.) in Cell Biology from Duke University between 2008 and 2014.
Tune Therapeutics
1 followers
With its versatile and powerful TEMPO epigenomic control platform, Tune Therapeutics is pioneering a new therapeutic modality that can fine-tune any gene network and unlock the full power and potential of regenerative medicine. With deep experience and a passionate commitment to exploration and innovation, Tune is driving through an inflection point in the history of genetic medicine: from targeting a limited range of rare conditions, to addressing thousands of common and complex diseases for which no curative treatment is available.